DB18568InvestigationalCell transplant therapies
CLL1-CD33 compound chimeric antigen receptor T cells: Overview.
- Mechanism
- Curator reviewed
Pharmacologically active on Myeloid cell surface antigen CD33 and C-type lectin domain family 12 member A
- Also known as
- Chimeric Antigen Receptor immunotherapy directed against CLL-1 and CD33 · CLL1-CD33 cCAR
Resolves to
Targets
What you can answer from here — as of July 09, 2026
Which drugs share a target with CLL1-CD33 compound chimeric antigen receptor T cells, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account